Drug intelligence / Profile preview

amantadine hydrochloride intravenous solution

Development stage: Unknown
Lead developer: SHINKEI Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

MR-301 is an intravenous (IV) formulation of amantadine hydrochloride being developed for the treatment of severe traumatic brain injury (sTBI). It is designed to potentially reverse the effects of sTBI and improve cognitive functions in patients who are in minimally conscious and/or vegetative comatose states. The drug is administered through IV infusion with a dosing regimen that starts at 100 mg and escalates to 200 mg as maintenance dose, given twice daily for up to 3 weeks.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on amantadine hydrochloride intravenous solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amantadine hydrochloride intravenous solution.

Explore the full profile